Peer-reviewed veterinary case report
Survival in dogs with pituitary Cushing's treated twice daily
By García San José, Paula et al.·Published in The Veterinary record·2022·Department of Small Animal Medicine and Surgery, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with Cushing's syndrome, specifically pituitary-dependent hyperadrenocorticism, were treated with low doses of a medication called trilostane twice a day. The study found that these dogs had a median survival time of about 998 days, which is longer than what was previously reported for higher doses. Factors like older age, low body condition score, and the presence of skin lesions (calcinosis cutis) were linked to a shorter survival time. Overall, the low-dose trilostane treatment appears to be effective in managing this condition and extending the lives of affected dogs.
People also search for: dog Cushing's syndrome treatment · trilostane for dogs · pituitary-dependent hyperadrenocorticism prognosis
Abstract
BACKGROUND: Twice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systolic blood pressure (SBP) at diagnosis, in dogs with pituitary-dependent hypercortisolism (PDH) treated with low trilostane doses. METHODS: Medical records of 91 dogs newly diagnosed with PDH initially treated with 0.2-1.1 mg/kg of trilostane twice daily were retrospectively included. Survival times were calculated using the Kaplan-Meier estimator. Univariable and multivariable analysis were performed using the Cox proportional hazard regression analysis. RESULTS: Overall, median survival was 998 days (range 26-1832 days, 95% confidence interval = 755-1241 days). In the multivariable analysis, age (hazard ratio [HR] = 1.337, p < 0.001), presence of calcinosis cutis (HR = 5.271, p < 0.001), body condition score (BCS) ≤3/9 (HR = 8.100, p < 0.001) and higher platelet count (HR = 1.002, p = 0.022) were negatively correlated with survival. SBP was not associated with survival. CONCLUSIONS: Low-dose trilostane treatment twice daily provides slightly longer survival than previously reported for dogs with PDH treated once or twice daily at higher doses. Older age, presence of calcinosis cutis, low BCS and higher platelet count, but not systemic hypertension, are predictive of poorer prognosis in dogs with PDH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35460587/